Consumer Defensive
Clene Inc.(CLNN)
Live Price
Offline$6.01
+1.35% today
1Y Change
+46.59%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- -41.5%
- EPS Growth
- +53.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Clene Inc. (CLNN) is a Consumer Defensive stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $6.01 and up 46.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -41.5%, EPS growth of +53.3%, a dividend yield of 0.0%. What stands out right now is revenue -41.5%, EPS +53.3%, free cash flow +12.9% with operating margin -11541.5% and ROIC -188.6%. Valuation already assumes a fairly strong business story at price/sales 329.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLNN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-41.5% vs +1.7% peer median
Operating Margin
Below sector median
-11541.5% vs +6.6% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -41.5% and EPS is at +53.3%, with operating margin around -11541.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +3.2% | -9.2% | -18.7% |
2026 Mar 12, 2026 | -18.9% | -3.4% | -0.8% | +3.2% |
2025 Nov 13, 2025 | -41.7% | +16.7% | +20.0% | -7.3% |
Benchmark Edge
CLNN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLNN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLNN Max Drawdown
-68.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLNN and SPY.
Company Overview
Clene Inc.
NASDAQ
Clene Inc. is a biopharmaceutical company that focuses on the development of nanotechnology-based therapies for neurodegenerative diseases. Its primary purpose is to innovate and advance treatment options for conditions such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Founded on the principles of using clean-surfaced, highly catalytic nanocrystals, Clene Inc. strives to enhance cellular energy production, which is crucial for neuronal health and function. This company's work is particularly significant in the medical field, impacting the biotechnology and healthcare sectors by addressing unmet medical needs with novel treatment approaches. Through various clinical trials and research initiatives, Clene Inc. aims to bring groundbreaking solutions to market, potentially altering the landscape of neurotherapeutics. Based in the United States, Clene Inc. continues to push the boundaries of scientific innovation and plays a pivotal role in the pursuit of effective therapies for chronic and debilitating neurological conditions.
- Leadership
- Mr. Robert Etherington MBA
- Employees
- 76
- Street Address
- 6550 South Millrock Drive, Suite G50
- Mailing
- Salt Lake City, UT, 84121
- Region
- Salt Lake City, UT, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 329.0
- Price/Book
- โ
Growth
- Revenue
- -41.5%
- EPS
- +53.3%
- Free Cash Flow
- +12.9%
Profitability
- Gross Margin
- 78.5%
- Operating Margin
- -11541.5%
- Net Margin
- -13086.5%
- ROE
- 240.8%
- ROIC
- -188.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.